Scribble

Price Momentum

PFE is trading near the top of its 52-week range and above its 200-day simple moving average.
Price change

The price of PFE shares has increased $0.45 since the market last closed. This is a 1.74% rise.
Opened at $25.83.

The stock opened $0.02 lower than its previous close.

Key terms

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Sector

Industry

Employees

Founded

Website

Key stock statistics

1-day range

52-week range

Market cap

P/E ratio

Next earnings date

Dividend yield

Ex-dividend date

Dividend pay date

Market cap: $146.97B

A market capitalization between $10 billion and $200 billion places PFE in the large capitalization category.

Key terms

Smart score

Today 10:05am ET Pfizer call volume above normal and directionally bullish by TipRanks Today 8:21am ET Adaptive Biotechnologies enters two licensing agreements with Pfizer by TipRanks Today 7:50am ET Pfizer price target lowered to $28 from $29 at BofA by TipRanks Today 7:06am ET Pfizer’s Hold Rating: Navigating Loss of Exclusivity and Flat Growth Prospects by TipRanks Yesterday 11:39am ET Pfizer’s New Phase 1 Study: A Potential Breakthrough for Kidney Disease Treatment by TipRanks Dec 12, 2025 1:56pm ET Pfizer Stock (PFE) Gets Bearish 2026 Call from Morgan Stanley — Here’s Why by TipRanks Dec 12, 2025 1:00pm ET Moderately bullish activity in Pfizer with shareslittle changed by TipRanks Dec 12, 2025 8:25am ET Morgan Stanley Sticks to Their Hold Rating for Pfizer (PFE) by TipRanks Dec 12, 2025 8:16am ET Pfizer price target lowered to $28 from $32 at Morgan Stanley by TipRanks Dec 11, 2025 6:12am ET Ideaya Biosciences completes enrollment in OptimUM-02 trial by TipRanks Dec 10, 2025 8:26am ET Pfizer announces results from HER2CLIMB-05 trial by TipRanks Dec 10, 2025 7:16am ET J.P. Morgan Remains a Hold on Pfizer (PFE) by TipRanks Dec 10, 2025 6:21am ET Pfizer price target raised to $29 from $28 at HSBC by TipRanks Dec 09, 2025 2:10pm ET FDA probe into COVID vaccines includes adults, Bloomberg reports by TipRanks Dec 09, 2025 2:05pm ET FDA to investigate COVID vaccine safety across age groups by TipRanks Dec 09, 2025 10:50am ET Analysts Offer Insights on Healthcare Companies: Fennec Pharmaceuticals (FENC) and Pfizer (PFE) by TipRanks Dec 09, 2025 10:40am ET Pfizer’s Fosun-partnered GLP-1 drug more aligned with orforglipron, Leerink says by TipRanks Dec 09, 2025 7:25am ET Guggenheim Sticks to Their Buy Rating for Pfizer (PFE) by TipRanks Dec 09, 2025 7:25am ET Structure Therapeutics Stock (GPCR) Spikes 102% as Obesity Trial Beats Eli Lilly, Novo Nordisk by TipRanks Dec 09, 2025 6:35am ET Pfizer signs exclusive collaboration and license agreement with YaoPharma by TipRanks Dec 08, 2025 1:15pm ET Mixed options sentiment in Pfizer with shares up 0.13% by TipRanks Dec 08, 2025 1:10pm ET Wave Life Sciences Stock (WVE) Soars 135% on Obesity Drug Results by TipRanks Dec 08, 2025 2:32am ET LLY, PFE: Eli Lilly’s Mounjaro, Pfizer’s Cancer Drug Added to China’s State Insurance List by TipRanks Dec 07, 2025 1:50pm ET Eli Lilly, Pfizer, Johnson secure spots on China’s drug catalog, Bloomberg says by TipRanks Dec 07, 2025 12:35pm ET Pfizer presents results from the Phase 3 BASIS study on HYMPAVZI by TipRanks Dec 06, 2025 4:00am ET Lennar, Pfizer, Cloudflare, Symbotic, Workday: Trending by Analysts by TipRanks Dec 05, 2025 1:46pm ET Trump Weekly: President approves U.S. manufacturing of ‘tiny cars’ by TipRanks Dec 05, 2025 1:45pm ET Mixed options sentiment in Pfizer with shares up 1.15% by TipRanks Dec 04, 2025 5:12pm ET Salesforce (CRM) Wins AstraZeneca Deal, Becomes the Unified Global Platform by TipRanks Dec 04, 2025 10:16am ET FDA shift in drug study requirements sends trial runners lower by TipRanks Dec 04, 2025 9:51am ET FDA to reduce number of trials required for drug approvals, STAT reports by TipRanks

1-year income & revenue

Total revenue: $63.63B (1Y), $16.65B (Q3)

Total Revenue increased 8.77% since last year and increased 13.66% since last quarter.
Net income: $8.02B (1Y), $3.54B (Q3)

Net Income increased 276.0% since last year and increased 22.74% since last quarter.
Earnings per share: $1.41 (1Y), $0.62 (Q3)

EPS increased 274.7% since last year and increased 22.57% since last quarter.

Key terms

analyst rating

buy
hold
sell

1-year stock price forecast

$ Market cap P/E ratio $ Price 1d change 52-week range

How competitors are chosen

PFE's competitors are included in the Health Technology sector and Pharmaceuticals: Major group
Market cap: $146.97B

A market capitalization between $10 billion and $200 billion places PFE in the large capitalization category.